Elicio Therapeutics (NASDAQ:ELTX) & Cardiff Oncology (NASDAQ:CRDF) Critical Contrast

Cardiff Oncology (NASDAQ:CRDF) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Cardiff Oncology and Elicio Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%
Elicio Therapeutics	N/A	-1,266.43%	-139.94%

Earnings & Valuation

This table compares Cardiff Oncology and Elicio Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$508,000.00	138.64	-$45.85 million	($0.60)	-1.51
Elicio Therapeutics	N/A	N/A	-$39.57 million	($2.17)	-1.42

Elicio Therapeutics has lower revenue, but higher earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cardiff Oncology has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Elicio Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cardiff Oncology and Elicio Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1	4	2	0	2.14
Elicio Therapeutics	1	1	4	0	2.50

Cardiff Oncology currently has a consensus target price of $7.50, suggesting a potential upside of 728.45%. Elicio Therapeutics has a consensus target price of $19.75, suggesting a potential upside of 539.16%. Given Cardiff Oncology’s higher possible upside, equities analysts plainly believe Cardiff Oncology is more favorable than Elicio Therapeutics.

Insider and Institutional Ownership

16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 8.5% of Cardiff Oncology shares are held by company insiders. Comparatively, 50.9% of Elicio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Elicio Therapeutics beats Cardiff Oncology on 7 of the 13 factors compared between the two stocks.

About Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.